Evofem Biosciences, Inc. EVFM was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 38.7% in the past one-month time frame.
The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Evofem Biosciences currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Evofem Biosciences, Inc. Price
Evofem Biosciences, Inc. price | Evofem Biosciences, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Akcea Therapeutics, Inc. AKCA, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Akcea Therapeutics, Inc. (AKCA) : Free Stock Analysis Report
Neothetics, Inc. (EVFM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research